However, for the risk of major amputations, there are no difference between these 2 groups.

The treatment effects of fenofibrate in FIELD study were irrespective of the level of glycaemic control and background use or not of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers. In Heart Protection study, it showed no difference in amputation rates between groups, despite substantial reductions in total cholesterol and LDL cholesterol levels, and modest changes in triglyceride and HDL cholesterol levels. These findings suggest that the effect of fenofibrates in reducing amputation risk is non-lipid mediated, and beyond blood pressure and glycaemic measures.

These findings, could lead to a change in the standard for the prevention of diabetes-relate amputations.